Given the limited literature addressing the impact of thromboplastin reagent variability in antiphospholipid syndrome, particularly in triple-positive patients, our case report provides timely and clinically relevant insights that may assist both clinical laboratories and physicians in optimizing anticoagulation monitoring strategies. This evidence concerns the gene F3 and antiphospholipid syndrome.